Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Balazs Halmos

Showing results (51-60 of 221) with videos related to

Pageof 23
Sort By:
Clinical Lung Cancer|March 10, 2024
Perioperative Immunotherapy for Non-Small Cell Lung Cancer: Practical Application of Emerging Data and New ChallengesAngelica D'Aiello, Brendon Stiles, Nitin Ohri, et al.
Expert Opinion on Therapeutic Targets|May 4, 2021
MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapiesMatthew Lee, Prantesh Jain, Feng Wang, et al.
Targeted Oncology|December 28, 2022
Emerging Biomarkers in Immune Oncology to Guide Lung Cancer ManagementHoussein Safa, Fawzi Abu Rous, Neel Belani, et al.
Oncotarget|October 23, 2014
AXL kinase as a novel target for cancer therapyXiaoliang Wu, Xuewen Liu, Sanjay Koul, et al.
Translational Lung Cancer Research|March 26, 2015
EGFR molecular testing in African-American non-small cell lung cancer patients - a review of discrepant dataBradley T Clifford, Pingfu Fu, Nathan A Pennell, et al.
JTO Clinical and Research Reports|September 30, 2021
Revolving Door of Histologic Transformation-Tumor Heterogeneity Complicating the Management of <i>EGFR</i>-Mutated Lung Adenocarcinoma: A Case of Jekyll and HydeMichael Wysota, Saeed Asiry, Yitzhak Goldstein, et al.
Future Oncology (London, England)|August 8, 2020
Making the case for EGFR TKI sequencing in <i>EGFR</i> mutation-positive NSCLC: a GioTag study US patient analysisBruce Feinberg, Balazs Halmos, Rasim Gucalp, et al.
Molecular Carcinogenesis|November 29, 2011
Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cellsXiaoqi Wang, Guangyuan Li, Antai Wang, et al.
Acta Oncologica (Stockholm, Sweden)|February 1, 2021
Spectrum of PD-1 and PD-L1 inhibitor cutaneous adverse events in skin of color: a retrospective, single-institutional study in an urban communityTracy Ngo, Claudia Hossain, Anthony K Guzman, et al.
Pathology Oncology Research : POR|July 3, 2024
Advancing neoadjuvant therapies in resectable non-small cell lung cancer: implications for novel treatment strategies and biomarker discoveryHyein Jeon, Rajvi Gor, Angelica D'Aiello, et al.
Pageof 23

Showing results (51-60 of 221) with videos related to

Sort By:
Pageof 23
Clinical Lung Cancer|March 10, 2024
Perioperative Immunotherapy for Non-Small Cell Lung Cancer: Practical Application of Emerging Data and New ChallengesAngelica D'Aiello, Brendon Stiles, Nitin Ohri, et al.
Expert Opinion on Therapeutic Targets|May 4, 2021
MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapiesMatthew Lee, Prantesh Jain, Feng Wang, et al.
Targeted Oncology|December 28, 2022
Emerging Biomarkers in Immune Oncology to Guide Lung Cancer ManagementHoussein Safa, Fawzi Abu Rous, Neel Belani, et al.
Oncotarget|October 23, 2014
AXL kinase as a novel target for cancer therapyXiaoliang Wu, Xuewen Liu, Sanjay Koul, et al.
Translational Lung Cancer Research|March 26, 2015
EGFR molecular testing in African-American non-small cell lung cancer patients - a review of discrepant dataBradley T Clifford, Pingfu Fu, Nathan A Pennell, et al.
JTO Clinical and Research Reports|September 30, 2021
Revolving Door of Histologic Transformation-Tumor Heterogeneity Complicating the Management of <i>EGFR</i>-Mutated Lung Adenocarcinoma: A Case of Jekyll and HydeMichael Wysota, Saeed Asiry, Yitzhak Goldstein, et al.
Future Oncology (London, England)|August 8, 2020
Making the case for EGFR TKI sequencing in <i>EGFR</i> mutation-positive NSCLC: a GioTag study US patient analysisBruce Feinberg, Balazs Halmos, Rasim Gucalp, et al.
Molecular Carcinogenesis|November 29, 2011
Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cellsXiaoqi Wang, Guangyuan Li, Antai Wang, et al.
Acta Oncologica (Stockholm, Sweden)|February 1, 2021
Spectrum of PD-1 and PD-L1 inhibitor cutaneous adverse events in skin of color: a retrospective, single-institutional study in an urban communityTracy Ngo, Claudia Hossain, Anthony K Guzman, et al.
Pathology Oncology Research : POR|July 3, 2024
Advancing neoadjuvant therapies in resectable non-small cell lung cancer: implications for novel treatment strategies and biomarker discoveryHyein Jeon, Rajvi Gor, Angelica D'Aiello, et al.
Pageof 23